search for




 

Medical Treatment of Progression of Myopia
Ann Optom Contact Lens 2018;17:1-4
Published online March 25, 2018
© 2018 The Korean Optometry & Contact Lens Study Society

Ungsoo Samuel Kim, MD, PhD1,2

Department of Ophthalmology, Kim's Eye Hospital1, Seoul, Korea
Department of ophthalmology, Konyang University College of Medicine2, Daejeon, Korea
Correspondence to: Ungsoo Samuel Kim, MD, PhD
Department of Ophthalmology, Kim's Eye Hospital, #136 Youngshin-ro, Youngdeungpo-gu, Seoul 07657, Korea
Tel: 82-2-2639-7517, Fax: 82-2-2677-9214
E-mail: ungsookim@kimeye.com
Received December 17, 2017; Revised December 26, 2017; Accepted December 26, 2017.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
The prevalence of myopia is up to 80% in young Korean population. The myopia can develop serious complications such as choroidal neovascularization, retinal detachment and glaucoma. As a result, several studies to prevent progression of myopia have been conducted. Among them, muscarinic antagonists are the more effective at slowing progression than other methods including orthokeratology and designed glasses. Recent studies have reported that low-dose atropine is also effective to slow progression of the myopia and it has fewer complications than high-dose atropine. However, long term side effect has not been clarified, and the commercial low-dose atropine is not available currently in Korea. Thus, in-depth studies about low-dose atropine should be considered.
Keywords : Atropine; Muscarine antagonist; Myopia


June 2018, 17 (2)